Sign up Australia
Proactive Investors - Run By Investors For Investors

Resapp Health to restart respiratory app study after enhancing its technology

Doctors Without Borders is not proceeding with its evaluation of the app.
A woman coughing
An improved audio recording app will now be deployed

Resapp Health Ltd (ASX:RAP) is planning to restart the U.S. paediatric clinical study of its “ResAppDx” app to detect respiratory diseases, this U.S. winter.

The company’s smartphone app works by using algorithms to analyse the sound of a patient’s cough and provide a diagnosis.

To improve the data-gathering element of the study, ResApp will now be regularly present onsite conducting clinical study team training, reviewing enrolment procedures and verifying data.

This is to help ensure that high-quality cough sounds are collected as early as possible during the patient’s hospital visit and prior to any treatment known to affect cough analysis.

Furthermore, an improved audio recording smartphone application incorporating built-in checklists, automated background noise estimation and additional visual aids will be deployed.

This is to support the data collection teams and eliminate inappropriate collection of cough data with background noise contamination.

However, Doctors Without Borders is not proceeding with its evaluation of ResAppDx, following the review of the issues identified in Resapp’s earlier study and the high cost of keeping the project open.

ResApp and Doctors Without Borders will maintain their collaborative relationship and seek opportunities for field testing the technology once the issues have been resolved.

All sites have reaffirmed their intention to rerun the updated study and are targeting to restart the study before the beginning of the U.S. winter season.





Register here to be notified of future RAP Company articles
View full RAP profile View Profile

ResApp Health Ltd Timeline

Related Articles

GW_Pharma.png
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
picture of seeds
July 18 2017
Finncap's revenue forecasts were upgraded by 6% and 7% to £72.2mln and £79.5mln for the full year 2017 and 2018 respectively.
picture of drug research
August 23 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use